Ignite Creation Date:
2025-12-24 @ 10:49 PM
Ignite Modification Date:
2026-01-06 @ 7:39 PM
Study NCT ID:
NCT06302569
Status:
RECRUITING
Last Update Posted:
2025-09-09
First Post:
2024-02-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
Sponsor:
Giuseppe Procopio
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-05-30
Start Date Type:
ACTUAL
Primary Completion Date:
2027-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-05
Completion Date Type:
ESTIMATED
First Submit Date:
2024-02-16
First Submit QC Date:
None
Study First Post Date:
2024-03-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-02
Last Update Post Date:
2025-09-09
Last Update Post Date Type:
ESTIMATED